Announcements & Notices

Total:149 items
Total: 149 items
  • 23
    2024-02
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT DOSE OF NEXT-GENERATION EGFR EXON20INS INHIBITOR ABSK112 COMPLETED BY ABBISKO THERAPEUTICS
  • 06
    2024-02
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS RECEIVED UPFRONT PAYMENT UPON THE ENTRY INTO A LICENSING AGREEMENT FOR PIMICOTINIB (ABSK021) WITH MERCK
  • 05
    2024-02
    Monthly Returns
    Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
  • 01
    2024-02
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE POST-IPO RSU SCHEME
  • 09
    2024-01
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - CSF-1R INHIBITOR PIMICOTINIB GRANTED ODD BY EMA
  • 05
    2024-01
    Monthly Returns
    Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
  • 03
    2024-01
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - CD73 INHIBITOR ABSK051 COMPLETED THE FIRST PATIENT DOSE
  • 14
    2023-12
    Announcements and Notices
    VOLUNTARY ANNOUNCEMENT - CSF-1R INHIBITOR PIMICOTINIB (ABSK021) GRANTED FAST TRACK DESIGNATION BY U.S. FDA
  • 06
    2023-12
    Monthly Returns
    Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
  • 04
    2023-12
    Announcements and Notices
    INSIDE INFORMATION - ABBISKO REACHED A LICENSE AGREEMENT WITH MERCK FOR PIMICOTINIB (ABSK021)
Go to Page

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号   

Lang
En